Remifentanil is an ultra-short-acting synthetic opioid-class analgesic which might be increasingly used "off-label" as pain management during labour. Side effects in parturients during labour, and in the infant at birth are of particular concern, especially respiratory depression which is concentration-dependent, and can occur at levels as low as 3-5 ng mL -1 . The safety of such use, particularly in newborns due to remifentanil placental transfer, has not been fully demonstrated yet, partly due to the lack of a suitable non-invasive analytical method. The aim of our work was to develop a sensitive method to monitor the levels of remifentanil in neonates by a non-invasive sampling of umbi lical cord blood to support efficacy and safety trials. The presented LC-MS method is sensitive enough to reliably quantify remifentanil in just 20 µL of blood at only 0.3 ng mL -1 . The dried blood spot sample preparation included solvent extraction with subsequent solid-phase extraction. The method was validated in terms of accuracy, precision, recovery, matrix effect, and stability, and was successfully applied to a small pilot study. The estimated arterial blood concentrations at the time of delivery ranged from 0.2 to 0.3, and up to 0.9 ng mL -1 in neonatal, and maternal samples, respectively.
Keyphrases
- solid phase extraction
- liquid chromatography tandem mass spectrometry
- pain management
- molecularly imprinted
- cord blood
- simultaneous determination
- high performance liquid chromatography
- liquid chromatography
- chronic pain
- gas chromatography mass spectrometry
- tandem mass spectrometry
- ms ms
- depressive symptoms
- pregnant women
- gestational age
- gas chromatography
- ultra high performance liquid chromatography
- ionic liquid
- pregnancy outcomes
- birth weight
- sleep quality
- preterm infants